Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro

Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day

Share this article:

Redefining Joint Health: Gnosis by Lesaffre Showcases MyCondro™ at CMA Innovation Day

At the recent Innovation Day seminar hosted by Complementary Medicines Australia (CMA), Gnosis by Lesaffre, led by Jose Pinedo Rivera, Product Manager, had the opportunity to present MyCondro™ to an engaged audience of over 250 industry professionals. The session, “Keeping Pace with a Changing World: MyCondro™ Disrupts the Chondroitin Sulfate Market,” was well received, sparking interest and conversations around the future of joint health solutions. 

Addressing Industry Challenges With Proven Science

MyCondrostood out as a breakthrough solution addressing the limitations of animal-based chondroitin, including supply chain variability, risk of contamination, and ethical concerns. Through the presentation, Gnosis highlighted how this fermentation-derived ingredient delivers 45% higher bioavailability, proven clinical efficacy at a lower dosage, and consistent purity that surpasses regulatory standards. As the world shifts toward cleaner, more responsible nutraceuticals, MyCondroemerged as a compelling option for brands looking to innovate and meet consumer expectations. 

Engaging One-to-One: Bringing Innovation Closer

In addition to the presentation, The Gnosis booth at the CMA event allowed connection with attendees in more personal, one-to-one discussions. These interactions offered a valuable platform to explain further why MyCondro matters—its scientific foundation, production innovation, and potential for expanded applications in areas like metabolic health and inflammation management. Overall, the seminar was a successful moment to communicate not just what Gnosis offers, but why and how the company is leading the transformation of the joint health category. 

Furthermore, the structure of MyCondro closely resembles human synovial fluid, which may contribute to its efficacy in promoting joint health. Its low molecular weight and homogeneous composition enhance its bioactivity, making it a promising option for individuals seeking to maintain joint function and mobility.  

Do you need more information about MyCondro™ or have any outstanding questions? Please do not hesitate to contact us; our expert team will happily answer!  

Other Active Ingredients

Latest news

CORPORATE HEADQUARTER
101 rue de Menin
59700 Marcq-en-Baroeul
France

Subscribe to our newsletter

The latest news, articles, and resources, sent to your inbox twice a month. 

The information provided here is, to the best of our knowledge, true and accurate. However, our products must only be used in compliance with local laws and regulations. We cannot guarantee the freedom of use for every intended application or country. These statements may not have been evaluated by your local Food and Drug Administration. Our products are not intended to diagnose, treat, cure, or prevent any disease. A healthy, balanced and diversified diet should fulfill all nutritional needs.